MXCT|EPS -$0.09 vs -$0.08 est (-10.3%)|Rev $7.3M|Net Loss $9.6MCompany Overview
MaxCyte, Inc. is a cell-engineering company providing platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics.
Key Financial Figures
For the full year 2025, MaxCyte reported a total revenue of $33.0 million. The company’s basic and diluted net loss per share (EPS) for 2025 was $(0.42). In the fourth quarter of 2025, total revenue was $7.3 million , while the basic and diluted net loss per share was $(0.09).
Additional Financial Insights
MaxCyte ended 2025 with $155.6 million in total cash, cash equivalents, and investments. During the year, the company generated a gross profit of $26.8 million, representing an 81% gross margin , and successfully reduced its annual cash burn by more than $16 million.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.